TY - JOUR
T1 - Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper.
AU - Silvestris, Nicola
AU - Argentiero, Antonella
AU - Beretta, Giordano Domenico
AU - Di Bartolo, Paolo
AU - Montagnani, Monica
AU - Danesi, Romano
AU - Ferrari, Pietro
AU - D'Oronzo, Stella
AU - Gori, Stefania
AU - Russo, Antonio
AU - Acquati, Silvia
AU - Gallo, Marco
N1 - Publisher Copyright:
© 2020 The Author(s)
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/8/15
Y1 - 2020/8/15
N2 - The growing insights in the next-generation immunotherapy and the state-of-the-art advancement in targeted-agents significantly improved clinical outcome of cancer patients by pointing towards a unexplored Achilles’ heel. Novel toxicity profiles have been uncovered, representing unmet medical needs. Thus, a panel of expert provide comprehensive pharmacological and clinical evidence, to provide a patient-tailored approach to metabolic adverse events associated with novel anti-cancer treatments. Prompted by the need of a multidisciplinary cooperation, a working group of Associazione Italiana Oncologia Medica (AIOM), Associazione Medici Diabetologi (AMD) and Società Italiana Farmacologia (SIF) examined the available literature data. The identification of patient risk profile and the characterization of metabolic effects of novel anti-tumour drugs is clearly a clinical challenge that can be addressed by a multidisciplinary clinical approach. Therefore, this review pinpoints the relevance of the challenging profiling of the patient suffering from dysmetabolic conditions induced by the novel therapeutics in medical oncology.
AB - The growing insights in the next-generation immunotherapy and the state-of-the-art advancement in targeted-agents significantly improved clinical outcome of cancer patients by pointing towards a unexplored Achilles’ heel. Novel toxicity profiles have been uncovered, representing unmet medical needs. Thus, a panel of expert provide comprehensive pharmacological and clinical evidence, to provide a patient-tailored approach to metabolic adverse events associated with novel anti-cancer treatments. Prompted by the need of a multidisciplinary cooperation, a working group of Associazione Italiana Oncologia Medica (AIOM), Associazione Medici Diabetologi (AMD) and Società Italiana Farmacologia (SIF) examined the available literature data. The identification of patient risk profile and the characterization of metabolic effects of novel anti-tumour drugs is clearly a clinical challenge that can be addressed by a multidisciplinary clinical approach. Therefore, this review pinpoints the relevance of the challenging profiling of the patient suffering from dysmetabolic conditions induced by the novel therapeutics in medical oncology.
KW - diabetes
KW - dyslipidemia
KW - hypercholesterolemia
KW - hyperglycemia
KW - hypertriglyceridemia
KW - immunotherapy
KW - metabolic effect
KW - targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85089819081&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089819081&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2020.103066
DO - 10.1016/j.critrevonc.2020.103066
M3 - Review article
C2 - 32853883
AN - SCOPUS:85089819081
VL - 154
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
M1 - 103066
ER -